Provided by Tiger Trade Technology Pte. Ltd.

Femasys Inc

2.78
+0.04001.46%
Post-market: 2.780.00000.00%19:30 EDT
Volume:16.20K
Turnover:44.86K
Market Cap:23.28M
PE:-0.63
High:2.83
Open:2.81
Low:2.74
Close:2.74
52wk High:22.20
52wk Low:2.02
Shares:8.38M
Float Shares:6.31M
Volume Ratio:0.20
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4145
EPS(LYR):-9.4201
ROE:-424.97%
ROA:-84.22%
PB:5.78
PE(LYR):-0.30

Loading ...

Femasys Partners with CapexMD to Offer Financing for FemaSeed Fertility Portfolio

Reuters
·
Sep 09

Femasys registers to sell 28.12M shares of common stock for holders

TIPRANKS
·
Sep 04

Femasys - Files for Resale of up to 28,124,997 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 04

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

GlobeNewswire
·
Aug 26

Femasys announces FDA approval of FemBloc modular premarket approval application

TIPRANKS
·
Aug 19

Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device

Reuters
·
Aug 19

Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States

THOMSON REUTERS
·
Aug 19

Femasys - Fembloc Approved for Marketing in Europe and Select International Markets

THOMSON REUTERS
·
Aug 19

Femasys is Maintained at Buy by Lake Street

Dow Jones
·
Aug 19

Femasys price target lowered to $10 from $30 at Lake Street

TIPRANKS
·
Aug 18

Femasys price target lowered to $10 from $30 at Maxim

TIPRANKS
·
Aug 16

Femasys Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate

Benzinga Earnings
·
Aug 15

Femasys Q2 Net Loss Narrows 2.55% to $4.47 Million; Net Sales Drop 18.9% to $331,827

Reuters
·
Aug 15

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

THOMSON REUTERS
·
Aug 15

Maxim Group Reaffirms Their Buy Rating on Femasys (FEMY)

TIPRANKS
·
Aug 14

Femasys Inc : Maxim Group Adjusts Target Price to $10 from $30 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Aug 13

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

GlobeNewswire
·
Aug 12

Femasys Files Form 3 for Chief Clinical-Medical Affairs Jeffrey Gerald Mifek

Reuters
·
Aug 12

Femasys CEO Kathy Lee-Sepsick Acquires USD 50,000 in Common Shares

Reuters
·
Aug 12